BNTC Share Price | Benitec Biopharma, Inc. Stock Analysis & Recommendation

Q: How big is Benitec Biopharma, Inc.?

Market Cap: As of Jun 18, Benitec Biopharma, Inc. has a market capitalization of 405.31 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters ending in March 2025, December 2024, September 2024, and June 2024, the company reported net sales of 0.00 million and a net profit of -26.49 million.Balance Sheet Snapshot: As of June 2024, the company's shareholder's funds amounted to 47.25 million, while total assets were reported at 52.21 million.

Q: What does Benitec Biopharma, Inc. do?

Overview: Benitec Biopharma, Inc. is a clinical-stage biotechnology company focused on the development of genetic medicines within the Pharmaceuticals & Biotechnology industry.Financial Snapshot: Most recent Net Profit: -9 Million (Quarterly Results - Mar 2025) Market cap: USD 405.31 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.06 Return on Equity: -27.93% Price to Book: 4.15Contact Details: Address: Level 14, 114 William St, MELBOURNE VIC: 3000 Tel: 61 3 86927222 Website: https://benitec.com/

Q: Is Benitec Biopharma, Inc. technically bullish or bearish?

As of 12 September 2025, the technical trend for Benitec Biopharma, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish trend, while the weekly KST and Dow Theory also reflect a mildly bearish outlook. The MACD shows bullish momentum on the weekly and mildly bullish on the monthly, but this is offset by the bearish signals from the KST and Dow Theory. Bollinger Bands are bullish across both time frames, but the overall sentiment remains cautious due to the daily indicators. There is no available return data to compare the company's performance against the S&P 500.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

31.06 k

Shareholding (Dec 2025)

FII

5.47%

Held by 14 FIIs

DII

82.46%

Held by 12 DIIs

Promoter

2.29%

How big is Benitec Biopharma, Inc.?

22-Jun-2025

As of Jun 18, Benitec Biopharma, Inc. has a market capitalization of 405.31 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -26.49 million for the latest four quarters. As of June 2024, shareholder's funds were 47.25 million and total assets were 52.21 million.

View full answer

What does Benitec Biopharma, Inc. do?

22-Jun-2025

Benitec Biopharma, Inc. is a clinical-stage biotechnology company focused on developing genetic medicines. As of March 2025, it has a market cap of $405.31 million and reported a net profit loss of $9 million.

View full answer

Is Benitec Biopharma, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, Benitec Biopharma, Inc. shows a mildly bearish trend due to daily moving averages and bearish signals from KST and Dow Theory, despite some bullish momentum in the MACD and Bollinger Bands.

View full answer

Compare Benitec Biopharma, Inc. with Similar Stocks

Avalon GloboCare Corp.Monopar Therapeutics, Inc.Atreca, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 413 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.01

Return on Equity

-20.79%

Price to Book

2.20

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-12 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-16.93%

6 Months

-23.07%

1 Year

-24.41%

2 Years

118.99%

3 Years

5061.9%

4 Years

401.85%

5 Years

-88.24%

Benitec Biopharma, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-3.43%

EBIT Growth (5y)

-217.58%

EBIT to Interest (avg)

-18.55

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.06

Sales to Capital Employed (avg)

0.00

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

76.72%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.20

EV to EBIT

-5.19

EV to EBITDA

-5.24

EV to Capital Employed

-208.72

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-20.79%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 12 Schemes (9.78%)

Foreign Institutions

Held by 14 Foreign Institutions (5.47%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -22.92% vs -41.18% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-13.30",
          "val2": "-10.70",
          "chgp": "-24.30%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.80",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-11.80",
          "val2": "-9.60",
          "chgp": "-22.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jun'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jun 2025 is 0.00% vs -100.00% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jun 2025 is -73.85% vs -11.22% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-41.40",
          "val2": "-22.30",
          "chgp": "-85.65%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.80",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-37.90",
          "val2": "-21.80",
          "chgp": "-73.85%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-13.30

-10.70

-24.30%

Interest

0.00

Exceptional Items

0.00

0.80

-100.00%

Consolidate Net Profit

-11.80

-9.60

-22.92%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is -22.92% vs -41.18% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Jun'25

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-41.40

-22.30

-85.65%

Interest

0.00

Exceptional Items

0.80

-0.00

Consolidate Net Profit

-37.90

-21.80

-73.85%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Jun 2025 is 0.00% vs -100.00% in Jun 2024

Consolidated Net Profit

YoY Growth in year ended Jun 2025 is -73.85% vs -11.22% in Jun 2024

All Annual Results

Company CV

About Benitec Biopharma, Inc.

Benitec Biopharma, Inc.

Pharmaceuticals & Biotechnology

Benitec Biopharma Inc. formerly Benitec Biopharma Limited, incorporated on April 7, 1995, a is a clinical-stage biotechnology company. The Company focused on the development of genetic medicines. The Company is developing a therapeutic technology platform that combines Ribonucleic acid (RNA) interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. The Company is using this technology, called Deoxyribonucleic acid (DNA)-directed RNA interference, or ddRNAi, to develop product candidates in chronic and life-threatening human disease areas including orphan disease and infectious disease. Benitec endeavors to develop and commercialize BB-301 for the treatment of Oculopharyngeal Muscular Dystrophy, or OPMD. The Company’s pipeline includes Oculopharyngeal Muscular Dystrophy (OPMD) Hepatitis B BB-103.

Company Coordinates

Company Details

Level 14, 114 William St , MELBOURNE VIC : 3000

Tel: 61 3 86927222

https://benitec.com/

Registrar Details